Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely do not align with the provided prescribing information. A minority of statements (notably those related to renal impairment, dose adjustment, withdrawal on discontinuation, and general adverse effects) are supported, while many bradycardia- and monitoring-related assertions are not explicitly supported by the labeled content.
Category Scores
Accurate Statements
Pregabalin is best known for side effects such as dizziness, sleepiness, and swelling.
5.5 Dizziness and Somnolence; 5.7 Peripheral Edema; 6 ADVERSE REACTIONS
Kidney impairment leading to higher pregabalin exposure, since pregabalin is cleared largely by the kidneys.
12 CLINICAL PHARMACOLOGY; 2.5 Patients with Renal Impairment
If bradycardia is new, worsening, or accompanied by symptoms such as fainting, near-fainting, chest pain, shortness of breath, or confusion, it should be treated as urgent and the prescriber should be contacted right away.
Not explicitly supported by provided label sections
Clinicians evaluate kidney function (creatinine clearance/eGFR) to confirm the dose is appropriate.
12 CLINICAL PHARMACOLOGY; 2.5 Patients with Renal Impairment
That can occur with reduced kidney function (which typically requires dose adjustment).
2.5 Patients with Renal Impairment
That can occur with drug interactions that increase sedation.
5.5 Dizziness and Somnolence
Stopping pregabalin suddenly can cause withdrawal-like symptoms in some people (especially after longer use).
5.6 Risks Associated with Abrupt or Rapid Discontinuation
Excessive alcohol or other sedatives used together.
5.5 Dizziness and Somnolence; 6 ADVERSE REACTIONS
That can occur with drug interactions that affect cardiac conduction indirectly.
5.5 Dizziness and Somnolence
Unsupported Statements
Some patients have reported slow heart rate (bradycardia).
Bradycardia is not listed as a common adverse reaction in the provided label sections.
Bradycardia is not among the most common, expected effects listed for pregabalin.
Label sections do not explicitly categorize bradycardia as a common adverse effect in the cited text.
When bradycardia occurs, clinicians typically check for other contributing factors (heart disease).
Label text does not specify checking heart disease as a bradycardia contributor.
When bradycardia occurs, clinicians typically check for other contributing factors (other medications).
Label text does not explicitly instruct evaluating concomitant medications as bradycardia contributors.
When bradycardia occurs, clinicians typically check for other contributing factors (electrolyte problems).
Label text does not explicitly require evaluating electrolytes as bradycardia contributors.
When bradycardia occurs, clinicians typically check for other contributing factors (overdose).
Label text does not specify evaluating overdose as a bradycardia contributor.
Several mechanisms or circumstances can link pregabalin to bradycardia.
No explicit label discussion of multiple mechanisms linking bradycardia to pregabalin in the provided sections.
Added effect from other drugs that slow heart rate.
Not explicitly stated in the provided label sections.
Beta blockers can contribute to pregabalin-associated bradycardia.
Not explicitly stated in the provided label sections.
Some calcium-channel blockers can contribute to pregabalin-associated bradycardia.
Not explicitly stated in the provided label sections.
Digoxin can contribute to pregabalin-associated bradycardia.
Not explicitly stated in the provided label sections.
Antiarrhythmics can contribute to pregabalin-associated bradycardia.
Not explicitly stated in the provided label sections.
Predisposition to conduction problems or existing cardiovascular disease can link pregabalin to bradycardia.
Not explicitly stated in the provided label sections.
Over-sedation or impaired autonomic balance in sensitive patients can link pregabalin to bradycardia.
Not explicitly stated in the provided label sections.
That can occur with missed or irregular dosing patterns.
Not explicitly stated in the provided label sections.
ECG is used to look for rhythm or conduction abnormalities.
Not explicitly stated in the provided label sections.
Electrolytes and other reversible causes are evaluated.
Not explicitly stated in the provided label sections.
Medication changes are individualized and should be made by a clinician.
Not explicitly stated in the provided label sections.
That can occur with missed or irregular dosing patterns.
Repeated; already listed as unsupported.
Hypothyroidism.
Not explicitly stated in the provided label sections.
Electrolyte abnormalities (potassium, magnesium).
Not explicitly stated in the provided label sections.
Dehydration.
Not explicitly stated in the provided label sections.
Recent illness, myocardial ischemia, or medication errors.
Not explicitly stated in the provided label sections.
Contradictions
Important Omissions
Lack of explicit bradycardia risk discussion or management guidance in the label excerpts; bradycardia-related monitoring and attribution is not described.
Importance:
Moderate
No explicit guidance on monitoring vital signs or evaluating concomitant heart-rate affecting medications in the provided sections.
Importance:
Moderate
No explicit statement about using ECG routinely to assess rhythm/conduction abnormalities in the provided label excerpts.
Importance:
Moderate
Boxed warnings or other safety warnings not present in the supplied excerpt; absence cannot be interpreted as absence from label overall.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims evaluated as unsupported; only a subset (renal impairment, dose adjustment, withdrawal on discontinuation, and general adverse effects) align with label content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Substantial number of non-label-supported claims (notably bradycardia-related and monitoring statements) reduce overall alignment.
Suggested Improvement
Limit assertions to statements supported by the provided label; for safety monitoring and physiology-related claims, either cite explicit label statements or remove unsupported claim assertions.